rs4810485 — CD40

CD40 — The B-Cell Activation Rheostat

CD40 is a transmembrane receptor expressed on B cells, monocytes, dendritic cells, and other antigen-presenting cells. When its ligand CD40L (CD154) — displayed on activated T helper cells — binds CD40, it triggers a cascade that drives B-cell proliferation, antibody class switching, and germinal center formation. In plain terms, CD40 is the molecular handshake between T cells and B cells that tells the immune system to mount a full adaptive response. The variant rs4810485, located in intron 1 of the CD40 gene, acts as a rheostat: the G allele keeps the dial turned up, driving higher CD40 expression; the T allele turns it down.

The Mechanism

rs4810485 sits within a regulatory region of the first intron of CD40. Studies using electrophoretic mobility shift assays in synovial fibroblasts and immune cells have shown allele-specific binding at this exact position¹¹ allele-specific binding at this exact position
The G allele creates a stronger protein-binding signal than the T allele across multiple cell types including Jurkat (T cells), HT1080 (fibroblasts), and primary immune cells. Preliminary evidence from a Letter implicates RBPJ, the canonical effector of NOTCH signaling²² NOTCH signaling
NOTCH is a cell-cell communication pathway that controls differentiation and activation thresholds in immune cells, as a candidate binding factor. If confirmed, the G allele may create a binding site that recruits RBPJ more efficiently, elevating CD40 transcription.

The downstream consequence is measurable and consistent: compared with the GG genotype, individuals carrying GT or TT genotypes show significantly reduced CD40 mRNA and protein expression³³ significantly reduced CD40 mRNA and protein expression
Both basal and stimulated conditions tested in CD14+ monocytes and CD19+ B cells in peripheral blood B cells and monocytes. This is not a subtle effect — GG homozygotes have approximately 33% more CD40 on the surface of primary human B lymphocytes than TT homozygotes.

The Evidence

Rheumatoid Arthritis: The CD40 locus was identified as an RA susceptibility locus in a GWAS meta-analysis of 3,393 cases and 12,462 controls⁴⁴ GWAS meta-analysis of 3,393 cases and 12,462 controls
Analysis combined multiple genome-wide studies and applied replication in 3,929 ACPA-positive RA cases and 5,807 controls (OR 0.87, p=8.2×10⁻⁹ for the T allele — the T allele is protective). A large UK replication study⁵⁵ large UK replication study
3,962 UK RA patients versus 3,531 healthy controls recruited across five centres confirmed the association (OR 0.86 per T allele, p=7.8×10⁻⁸ after meta-analysis).

Beyond disease onset, rs4810485 influences disease course: TT homozygotes show higher rates of joint destruction in ACPA-positive RA⁶⁶ higher rates of joint destruction in ACPA-positive RA
Primary cohort of 563 RA patients; ACPA-positive subset used; replicated in 393 ACPA-positive patients in NARAC cohort (p=0.003, replicated in an independent cohort at p=0.021), making it one of the first non-HLA genetic severity factors replicated in RA.

Systemic Lupus Erythematosus: In a combined Greek and Turkish cohort, the T allele was significantly under-represented in SLE patients⁷⁷ the T allele was significantly under-represented in SLE patients
509 SLE patients and 825 healthy controls across two cohorts (combined OR 0.63, 95% CI 0.53–0.74, p=2×10⁻⁸), with the same allele-specific expression pattern found in cases and controls alike.

Crohn's Disease and Multiple Sclerosis: rs4810485 is in tight linkage disequilibrium (r²=0.95) with rs1883832, a CD40 promoter variant. Studies of rs1883832 showed a novel association with Crohn's disease⁸⁸ novel association with Crohn's disease
Spanish cohort genotyped for rs1883832; CD patients vs population controls (OR 1.19, p=0.002) and replication in multiple sclerosis susceptibility (OR 1.12, p=0.025). Notably, the susceptibility allele for RA/SLE appears protective in MS — the CD40 locus shows disease-specific directional effects, implying that the optimal level of CD40 signaling differs across distinct autoimmune processes.

Graves' Disease and Therapeutic Relevance: In a precision medicine study of Graves' disease patients treated with iscalimab (an anti-CD40 monoclonal antibody), treatment responders were enriched for the G-allele haplotype⁹⁹ treatment responders were enriched for the G-allele haplotype
13 Graves disease patients treated with iscalimab; genotyped for rs4810485 and flanking CD40 SNPs while non-responders predominantly carried T-allele haplotypes (p=0.0008). This provides proof-of-concept that rs4810485 genotyping may one day guide selection of anti-CD40 pathway therapies.

Practical Actions

For GG carriers, the elevated CD40 expression on B cells creates the foundation for heightened autoimmune B-cell activity. The key implication is not a single actionable nutrient or supplement, but rather a set of monitoring priorities: early detection of autoimmune conditions, awareness of how anti-CD40L biologics may be particularly relevant if they are ever prescribed, and avoidance of exposures known to trigger autoimmunity in genetically predisposed individuals.

For TT homozygotes, the reduced CD40 expression appears protective against most autoimmune diseases studied — but the picture is complex. In multiple sclerosis, the low-CD40 T allele may increase susceptibility, and in RA patients who carry the TT genotype, evidence suggests faster joint destruction despite lower disease onset risk. TT carriers should still be monitored for RA if symptoms develop, as the TT genotype does not fully eliminate risk.

Interactions

CD40 rs4810485 acts within the broader adaptive immune network. The most relevant co-regulatory variants in the database are rs2476601 (PTPN22 R620W, affecting T-cell signaling threshold) and rs3087243 (CTLA4 CT60, the T-cell checkpoint). In individuals who carry risk alleles at multiple nodes of T-cell/B-cell co-stimulation, the combined dysregulation may be substantially greater than any single variant predicts. Functional studies specifically on the CD40–PTPN22 and CD40–CTLA4 combined effects are limited, but these variants all converge on the same germinal center reaction pathway. Future compound action entries in this category will capture these combined interactions when supported by published evidence.